Medicinal Cannabis and the Tyranny of Distance: Policy Reform Required for Optimizing Patient and Health System Net Benefit in Australia
In the evolution of any novel concept, there is a spectrum in the rate at which individuals adopt a new idea, a diffusion of innovation stretching from innovators to laggards [ 1]. Such a distribution is emerging globally in the rapidly evolving field of medicinal cannabis (MC). Countries such as Israel, the Netherlands and, more recently, Canada could be regarded as innovators [ 2, 3]. They have taken pragmatic health system- based responses to the needs of patients, facilitating access to those with highest expected net clinical benefit while con- ducting trials and studies in parallel. Even the USA, with its patchwork quilt of innovation and lack of federal oversight, is developing insights into what works for their patient populations, and what doesn't [ 4].